

# Jonathan Cebon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4262522/publications.pdf>

Version: 2024-02-01

158  
papers

17,738  
citations

30047

54  
h-index

14197

128  
g-index

162  
all docs

162  
docs citations

162  
times ranked

25380  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
2	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2012, 367, 1694-1703.	13.9	2,445
3	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. <i>Cell</i> , 2017, 170, 1109-1119.e10.	13.5	1,124
4	Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> , 2017, 545, 175-180.	13.7	1,068
5	CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. <i>Nature</i> , 2017, 549, 101-105.	13.7	624
6	Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. <i>Blood</i> , 2002, 100, 1362-1372.	0.6	338
7	Butyrophilin 2A1 is essential for phosphoantigen reactivity by $\hat{I}^3\hat{I}$ T cells. <i>Science</i> , 2020, 367, .	6.0	275
8	Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600 Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	0.8	266
9	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3815-3822.	0.8	244
10	Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. <i>Lancet</i> , The, 1996, 348, 1279-1281.	6.3	216
11	Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage. <i>Clinical Cancer Research</i> , 2006, 12, 764-771.	3.2	212
12	Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. <i>Blood</i> , 2005, 105, 1582-1589.	0.6	198
13	Long-Term Outcomes in Patients With <i>BRAF</i> V600 Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	0.8	196
14	Large Scale Identification of Human Hepatocellular Carcinoma-Associated Antigens by Autoantibodies. <i>Journal of Immunology</i> , 2002, 169, 1102-1109.	0.4	176
15	Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. <i>Blood</i> , 2005, 105, 2465-2472.	0.6	175
16	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> V600 Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	0.8	173
17	Endogenous haemopoietic growth factors in neutropenia and infection. <i>British Journal of Haematology</i> , 1994, 86, 265-274.	1.2	164
18	Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. <i>Blood</i> , 2004, 103, 1391-1397.	0.6	164

#	ARTICLE	IF	CITATIONS
19	The Regulatory T Cell-associated Transcription Factor FoxP3 Is Expressed by Tumor Cells. <i>Cancer Research</i> , 2008, 68, 3001-3009.	0.4	161
20	Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2020, 6, 1405.	3.4	157
21	Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. <i>Scientific Reports</i> , 2015, 5, 11198.	1.6	150
22	An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2007, 13, 3630-3636.	3.2	149
23	Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. <i>Cancer Cell</i> , 2013, 23, 618-633.	7.7	136
24	Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. <i>Clinical Cancer Research</i> , 2009, 15, 2123-2129.	3.2	127
25	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. <i>Cell Death and Disease</i> , 2019, 10, 342.	2.7	125
26	Regulatory T-Cell-mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 2166-2173.	3.2	119
27	ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. <i>Blood</i> , 2003, 102, 613-620.	0.6	118
28	IFN- $\gamma$ enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. <i>International Immunology</i> , 2002, 14, 367-380.	1.8	117
29	Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 4454-4459.	3.2	110
30	Rational approaches to human cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2003, 73, 3-29.	1.5	109
31	Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. <i>Oncotarget</i> , 2014, 5, 5782-5797.	0.8	109
32	IL-1 $\beta$ Enhances CD40 Ligand-Mediated Cytokine Secretion by Human Dendritic Cells (DC): A Mechanism for T Cell-Independent DC Activation. <i>Journal of Immunology</i> , 2002, 168, 713-722.	0.4	108
33	Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. <i>Blood</i> , 2003, 102, 1753-1763.	0.6	103
34	Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. <i>Blood</i> , 2008, 111, 2733-2743.	0.6	98
35	Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma. <i>Science Advances</i> , 2020, 6, eaax3223.	4.7	97
36	Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. <i>Nature Immunology</i> , 2021, 22, 851-864.	7.0	97

#	ARTICLE	IF	CITATIONS
37	Directions in the immune targeting of cancer: Lessons learned from the cancer testis Ag NY-ESO-1. <i>Immunology and Cell Biology</i> , 2006, 84, 303-317.	1.0	96
38	Melan-A specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4. <i>Clinical Cancer Research</i> , 2009, 15, 2507-2513.	3.2	96
39	CT-X antigen expression in human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13493-13498.	3.3	92
40	ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II. <i>Journal of Immunology</i> , 2009, 182, 1253-1259.	0.4	91
41	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017, 116, 1558-1563.	2.9	91
42	Characterising the phenotypic evolution of circulating tumour cells during treatment. <i>Nature Communications</i> , 2018, 9, 1482.	5.8	86
43	NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 2879-2890.	3.2	84
44	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11813-11818.	3.3	83
45	Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9363-9368.	3.3	82
46	Distinctive localization of antigen-presenting cells in human lymph nodes. <i>Blood</i> , 2009, 113, 1257-1267.	0.6	76
47	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 115-124.	1.3	76
48	Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1635-1646.	2.0	63
49	Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients. <i>Journal of Immunotherapy</i> , 2006, 29, 499-511.	1.2	62
50	Activin-A attenuates several human natural killer cell functions. <i>Blood</i> , 2009, 113, 3218-3225.	0.6	61
51	Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide. <i>Nature Communications</i> , 2018, 9, 1026.	5.8	61
52	Sex differences in oncogenic mutational processes. <i>Nature Communications</i> , 2020, 11, 4330.	5.8	60
53	Enhancement of Platelet Recovery After Myelosuppressive Chemotherapy by Recombinant Human Megakaryocyte Growth and Development Factor in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2852-2861.	0.8	59
54	The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. <i>Cancer Immunity</i> , 2004, 4, 9.	3.2	58

#	ARTICLE	IF	CITATIONS
55	Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1. <i>Clinical Cancer Research</i> , 2004, 10, 8396-8404.	3.2	55
56	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	1.3	53
57	Exogenous Peptides Presented by Transporter Associated with Antigen Processing (TAP)-Deficient and TAP-Competent Cells: Intracellular Loading and Kinetics of Presentation. <i>Journal of Immunology</i> , 2001, 167, 2529-2537.	0.4	52
58	A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma. <i>PLoS ONE</i> , 2012, 7, e48424.	1.1	52
59	BRAF Inhibitor-Driven Tumor Proliferation in a <i>KRAS</i> -Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition. <i>Journal of Clinical Oncology</i> , 2013, 31, e448-e451.	0.8	51
60	Clinical and pathological associations of the activating <i>RAC1</i> P29S mutation in primary cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1117-1125.	1.5	51
61	Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFR $\beta$ . <i>Neoplasia</i> , 2017, 19, 932-940.	2.3	50
62	Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10702-E10711.	3.3	50
63	The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 597-600.	1.5	49
64	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 411.	2.2	49
65	P2Y receptor signaling regulates phenotype and IFN- $\gamma$ secretion of human plasmacytoid dendritic cells. <i>Blood</i> , 2008, 111, 3062-3069.	0.6	48
66	A Long, Naturally Presented Immunodominant Epitope from NY-ESO-1 Tumor Antigen: Implications for Cancer Vaccine Design. <i>Cancer Research</i> , 2009, 69, 1046-1054.	0.4	48
67	<i>Fc</i> γ3 ligand expands <i>CD4<sup>+</sup>Fcγ3oxP3<sup>+</sup></i> regulatory <i>T</i> cells in human subjects. <i>European Journal of Immunology</i> , 2013, 43, 533-539.	1.6	47
68	Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy. <i>Oncologist</i> , 2018, 23, 849-851.	1.9	46
69	Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 1322-1334.	1.6	45
70	Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: Relation to disease severity, multiple organ dysfunction, and mortality. <i>Critical Care Medicine</i> , 2000, 28, 2344-2354.	0.4	44
71	PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. <i>Molecular Cancer</i> , 2017, 16, 112.	7.9	44
72	Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 297-302.	0.9	44

#	ARTICLE	IF	CITATIONS
73	Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX <sup>®</sup> . <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1625-1637.	2.0	41
74	Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. <i>Cancer Cell</i> , 2021, 39, 592-593.	7.7	41
75	Whole exome sequencing identifies a recurrent RQCD1</i>P131L mutation in cutaneous melanoma. <i>Oncotarget</i> , 2015, 6, 1115-1127.	0.8	40
76	FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.. <i>Oncotarget</i> , 2014, 5, 264-276.	0.8	38
77	Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-1. <i>Journal of Immunology</i> , 2006, 176, 5908-5917.	0.4	37
78	Mismatch in epitope specificities between IFN <sup>γ</sup> 3 inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma. , 2016, 4, 10.		35
79	Identifying and targeting determinants of melanoma cellular invasion. <i>Oncotarget</i> , 0, 7, 41186-41202.	0.8	35
80	Clinical promise of tumour immunology. <i>Lancet, The</i> , 1997, 349, S19-S22.	6.3	34
81	Influenza A Infection Enhances Cross-Priming of CD8+ T Cells to Cell-Associated Antigens in a TLR7- and Type I IFN-Dependent Fashion. <i>Journal of Immunology</i> , 2010, 185, 6013-6022.	0.4	34
82	Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion. <i>Oncotarget</i> , 2015, 6, 15953-15965.	0.8	34
83	Directed evolution for improved secretion of cancer <sup>®</sup> testis antigen NY-ESO-1 from yeast. <i>Protein Expression and Purification</i> , 2006, 48, 232-242.	0.6	33
84	Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. <i>Blood</i> , 2010, 116, 218-225.	0.6	31
85	Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 321-335.	2.0	31
86	Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX <sup>®</sup> , <sup>®</sup> vaccine in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 507-518.	2.0	31
87	A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. <i>Journal of Immunological Methods</i> , 2004, 291, 51-62.	0.6	29
88	Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells. <i>Frontiers in Oncology</i> , 2014, 4, 367.	1.3	29
89	Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. <i>BMC Medical Genomics</i> , 2013, 6, 40.	0.7	28
90	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	1.3	28

#	ARTICLE	IF	CITATIONS
91	The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. <i>British Journal of Haematology</i> , 1992, 80, 144-150.	1.2	27
92	Melanoma vaccines: developments over the past 10 years. <i>Expert Review of Vaccines</i> , 2011, 10, 853-873.	2.0	27
93	Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells. <i>BMC Cancer</i> , 2016, 16, 134.	1.1	27
94	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	3.2	27
95	Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma. <i>Frontiers in Oncology</i> , 2015, 5, 95.	1.3	26
96	A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2021, 7, 122.	2.0	23
97	Cancer exploiting complement: a clue or an exception?. <i>Nature Immunology</i> , 2008, 9, 1205-1206.	7.0	22
98	Frequent MAGE Mutations in Human Melanoma. <i>PLoS ONE</i> , 2010, 5, e12773.	1.1	22
99	Optimal Effector Functions in Human Natural Killer Cells Rely upon Autocrine Bone Morphogenetic Protein Signaling. <i>Cancer Research</i> , 2014, 74, 5019-5031.	0.4	22
100	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 5-12.	0.7	22
101	Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. <i>Cancer Immunity</i> , 2005, 5, 5.	3.2	22
102	Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 1999, 17, 82-82.	0.8	21
103	Systems analysis identifies miR-29b regulation of invasiveness in melanoma. <i>Molecular Cancer</i> , 2016, 15, 72.	7.9	21
104	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
105	Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. <i>Onc Immunology</i> , 2021, 10, 1908771.	2.1	21
106	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2021, 27, 5280-5288.	3.2	21
107	Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. <i>Expert Review of Vaccines</i> , 2010, 9, 617-629.	2.0	20
108	Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens. <i>International Journal of Cancer</i> , 2014, 135, 1842-1851.	2.3	20



#	ARTICLE	IF	CITATIONS
109	Perspective: cancer vaccines in the era of immune checkpoint blockade. <i>Mammalian Genome</i> , 2018, 29, 703-713.	1.0	20
110	Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. <i>BMC Nephrology</i> , 2020, 21, 391.	0.8	20
111	Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. , 2019, 7, 241.		19
112	Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2017, 22, 780-e65.	1.9	18
113	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 418-426.	1.2	18
114	Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 26-30.	0.7	18
115	Sphingosine-1-phosphate lyase is expressed by CD68 <sup>+</sup> cells on the parenchymal side of marginal reticular cells in human lymph nodes. <i>European Journal of Immunology</i> , 2014, 44, 2425-2436.	1.6	17
116	The Ets Transcription Factor <i>ELF5</i> Functions as a Tumor Suppressor in the Kidney. <i>Twin Research and Human Genetics</i> , 2011, 14, 316-322.	0.3	16
117	Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma. <i>Journal of Surgical Oncology</i> , 2018, 118, 915-921.	0.8	16
118	Evolving role of tumor antigens for future melanoma therapies. <i>Future Oncology</i> , 2014, 10, 1457-1468.	1.1	15
119	The role of circulating microRNA in hepatocellular carcinoma. <i>Frontiers in Bioscience - Landmark</i> , 2015, 20, 78-104.	3.0	15
120	Iterative sorting reveals CD133 <sup>+</sup> and CD133 <sup>-</sup> melanoma cells as phenotypically distinct populations. <i>BMC Cancer</i> , 2016, 16, 726.	1.1	15
121	A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response. <i>Journal of Investigative Dermatology</i> , 2020, 140, 869-877.e16.	0.3	15
122	Migratory cues controlling B-lymphocyte trafficking in human lymph nodes. <i>Immunology and Cell Biology</i> , 2021, 99, 49-64.	1.0	15
123	Stem Cell Media Culture of Melanoma Results in the Induction of a Nonrepresentative Neural Expression Profile. <i>Stem Cells</i> , 2012, 30, 336-343.	1.4	14
124	Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 4021-4023.	3.2	13
125	Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro. <i>Stem Cell Reviews and Reports</i> , 2016, 12, 156-161.	5.6	13
126	A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX <sup>®</sup> adjuvant. <i>Immunotherapy</i> , 2017, 9, 249-259.	1.0	13



#	ARTICLE	IF	CITATIONS
127	BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2020, 6, 114.	2.0	13
128	PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 672521.	2.2	13
129	Immunotherapy of advanced or metastatic melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 994-1006.	0.3	11
130	A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells. <i>Frontiers in Genetics</i> , 2013, 4, 209.	1.1	10
131	Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 990-1003.	1.6	10
132	Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. <i>Cancer Immunity</i> , 2005, 5, 3.	3.2	10
133	Immunotherapy of melanoma: Targeting defined antigens. <i>Australasian Journal of Dermatology</i> , 1997, 38, S66-S72.	0.4	9
134	Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein. <i>Molecular Immunology</i> , 2013, 54, 465-471.	1.0	9
135	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. <i>Pathology</i> , 2015, 47, 683-693.	0.3	9
136	Pharmacokinetic Analysis of Pegylated Megakaryocyte Growth and Development Factor in Humans. <i>Growth Factors</i> , 2000, 18, 215-226.	0.5	8
137	Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells. <i>Frontiers in Oncology</i> , 2015, 5, 36.	1.3	8
138	Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces. <i>Scientific Reports</i> , 2016, 6, 19709.	1.6	8
139	Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects. <i>Cancer Immunology, Immunotherapy</i> , 1998, 47, 191-197.	2.0	7
140	A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 157-164.	1.1	7
141	Cancer vaccines: Where are we going?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, S9-15.	0.7	7
142	Cancer stem cells in urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 585-590.	0.8	7
143	A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen. <i>PLoS ONE</i> , 2012, 7, e44707.	1.1	7
144	A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. <i>Cancer Reports</i> , 2019, 2, e1183.	0.6	7

#	ARTICLE	IF	CITATIONS
145	Effectiveness of dabrafenib in the treatment of patients with BRAF V600E-mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	0.6	6
146	Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. , 2021, 9, e003156.		6
147	<i>FOXP3</i> is not mutated in human melanoma. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 398-400.	1.5	5
148	A novel method for detecting antigen-specific human regulatory T cells. <i>Journal of Immunological Methods</i> , 2012, 377, 56-61.	0.6	5
149	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 5222-5234.	3.2	4
150	Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 55-67.	0.7	3
151	Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 76-86.	0.7	2
152	Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1107-1123.	1.3	2
153	Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses. <i>Cancers</i> , 2021, 13, 1805.	1.7	2
154	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. <i>Targeted Oncology</i> , 2016, 11, 149-156.	1.7	1
155	Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy"™™. <i>British Journal of Cancer</i> , 2017, 116, e15-e15.	2.9	1
156	Dendritic cell development. , 2004, , 103-112.		0
157	Melanoma Vaccines. , 2019, , 1-23.		0
158	Melanoma Vaccines. , 2020, , 1243-1265.		0